Q BioMed Inc.
QBIO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for QBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 5 of 6 signals
Market Cap
$15K
Cash Runway
1.1 moLead Asset
metastron (Approved)
Next Catalyst
Phase3_Topline · Dec 30, 2027Financial data as of Feb 28, 2023.
Tracking 2 pipeline candidates · 15 clinical trials · 3 catalysts for Q BioMed Inc..
Run Q BioMed Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Q BioMed Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 5 of 6 signals · derived from public data
1.1 months
OCF -$138K · Net income -$722K
Lead: Approved
2 candidates
3 upcoming, next in ~487d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Frequently asked questions
What is Q BioMed Inc.'s lead drug candidate?
Q BioMed Inc.'s most advanced tracked candidate is metastron (Approved) for Pain palliation in bone metastases.
What is Q BioMed Inc.'s next catalyst?
Q BioMed Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Tr" — expected December 30, 2027.
Who is the CEO of Q BioMed Inc.?
Mr. Denis D. Corin is the chief executive officer of Q BioMed Inc. (QBIO).
Where is Q BioMed Inc. headquartered?
Q BioMed Inc. (QBIO) is headquartered in New York, NY, United States.
What therapeutic areas does Q BioMed Inc. focus on?
Q BioMed Inc. develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Hematology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.